Clinical Trial Update: Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for E7777 in relapsed or refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma has completed recruitment with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• E7777 (E7777)

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2021-07-15